# Phase 1/2 disease trials recruiting: 116 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 116 trials in phase 1/2 for disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 disease trials: 116 rows for $5.80, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 116
- Recruiting or not yet: 116
- Read on: November 19, 2026

## Trials

The 25 newest of 116, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939295 | Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Phase 1/2 | Not yet recruiting | Parkinson's Disease (PD), Advanced Primary PD | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939295) |
| November 10, 2026 | NCT07929480 | A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Phase 1/2 | Not yet recruiting | Parkinson's Disease (PD), PD | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929480) |
| October 26, 2026 | NCT07894887 | EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) | Editas Medicine, Inc. | Phase 1/2 | Not yet recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894887) |
| October 7, 2026 | NCT07863180 | Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863180) |
| September 22, 2026 | NCT07832370 | A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Prion Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832370) |
| September 4, 2026 | NCT07804004 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease | CRISPR Therapeutics | Phase 1/2 | Not yet recruiting | Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804004) |
| September 1, 2026 | NCT07796620 | Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | Peking University People's Hospital | Phase 1/2 | Not yet recruiting | Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796620) |
| August 19, 2026 | NCT07773246 | Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD | Korro Bio, Inc. | Phase 1/2 | Recruiting | Urea Cycle Disorders, Inborn, Urea Cycle Disorders, Ornithine Transcarbamylase (OTC) Deficiency, Arginase 1 Deficiency... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773246) |
| July 31, 2026 | NCT07738107 | ATR 1072 in Participants With PRKAG2 Syndrome | Atrium Therapeutics | Phase 1/2 | Recruiting | Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738107) |
| July 29, 2026 | NCT07733349 | Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease | Shanghai UniXell Biotechnology Co., Ltd | Phase 1/2 | Recruiting | Parkinson's Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733349) |
| July 27, 2026 | NCT07728695 | Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Endometriosis, Adenomyosis, Chronic Pelvic Inflammatory Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728695) |
| July 24, 2026 | NCT07724873 | Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients | Tata Memorial Centre | Phase 1/2 | Recruiting | Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724873) |
| July 16, 2026 | NCT07709741 | Sustained Release Oral Formulation For Treatment Of Parkinsons Disease | University of Minnesota | Phase 1/2 | Not yet recruiting | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709741) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| July 9, 2026 | NCT07693140 | Low-Dose Radiotherapy for Alzheimer's Disease | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Alzheimer Dementia, Dementia, Alzheimer Dementia (AD), Alzheimer, Alzheimer s Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693140) |
| June 30, 2026 | NCT07675174 | PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT | Northwell Health | Phase 1/2 | Recruiting | GVHD - Graft-Versus-Host Disease | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675174) |
| June 16, 2026 | NCT07651319 | Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | The Methodist Hospital Research Institute | Phase 1/2 | Recruiting | Alzheimer Dementia (AD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651319) |
| June 11, 2026 | NCT07641010 | PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma | Shanghai Jiao Tong University School of Medicine | Phase 1/2 | Not yet recruiting | Hodgkin Lymphoma | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641010) |
| June 5, 2026 | NCT07629245 | Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of... | Assistance Publique Hopitaux De Marseille | Phase 1/2 | Recruiting | Crohn Disease (CD) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629245) |
| May 22, 2026 | NCT07603050 | A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease | Shanghai Vitalgen BioPharma Co., Ltd. | Phase 1/2 | Not yet recruiting | Gaucher Disease Type 3 | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603050) |
| May 22, 2026 | NCT07602751 | FMT for Pediatric SR-aGVHD | Bambino Gesù Hospital and Research Institute | Phase 1/2 | Recruiting | Acute Graft Versus Host Disease in Intestine | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602751) |
| May 22, 2026 | NCT07601425 | Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) | Atavistik Bio, Inc | Phase 1/2 | Recruiting | Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601425) |
| May 20, 2026 | NCT07599670 | A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's... | AbbVie | Phase 1/2 | Recruiting | Alzheimer's Disease | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599670) |
| May 8, 2026 | NCT07576699 | CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD) | Cellenkos, Inc. | Phase 1/2 | Not yet recruiting | Steroid Refractory Graft Versus Host Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576699) |
| April 22, 2026 | NCT07544160 | BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) | iCell Gene Therapeutics | Phase 1/2 | Not yet recruiting | Inflammatory Bowel Diseases (IBD) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544160) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of California, Los Angeles | 3 |
| Kanglin Biotechnology (Hangzhou) Co., Ltd. | 2 |
| Northwell Health | 2 |
| Cedars-Sinai Medical Center | 2 |
| University Hospital, Toulouse | 2 |
| Shanghai Vitalgen BioPharma Co., Ltd. | 2 |
| iRegene Therapeutics Co., Ltd. | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| University Medical Center Groningen | 2 |
| M.D. Anderson Cancer Center | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| University of Alabama at Birmingham | 1 |
| Tr1X, Inc. | 1 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 1 |
| Thomas Advanced Medical LLC | 1 |
| Massachusetts General Hospital | 1 |
| AC Immune SA | 1 |
| 4D Molecular Therapeutics | 1 |
| Venturis Therapeutics, Inc. | 1 |
| Essen Biotech | 1 |
| Korro Bio, Inc. | 1 |
| Vico Therapeutics B. V. | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| St Vincent's Hospital Melbourne | 1 |
| [GE Healthcare](https://specstream.ai/data/clinical-trials/company/ge-healthcare) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 62 |
| China | 18 |
| United Kingdom | 6 |
| Australia | 6 |
| France | 6 |
| Germany | 4 |
| Italy | 4 |
| Spain | 3 |
| Taiwan | 3 |
| Netherlands | 3 |
| South Korea | 3 |
| Brazil | 3 |
| Egypt | 2 |
| Switzerland | 2 |
| Canada | 2 |
| Denmark | 1 |
| Israel | 1 |
| Greece | 1 |
| Japan | 1 |
| Argentina | 1 |
| Norway | 1 |
| Bulgaria | 1 |
| Poland | 1 |
| India | 1 |
| New Zealand | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Community health centers in the United States](https://specstream.ai/data/businesses/community-health-centers/united-states)
- [Vocational and technical schools in the United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/united-states)
- [Payroll companies in the United States](https://specstream.ai/data/businesses/payroll-companies/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
- [Blinds and shades companies in the United States](https://specstream.ai/data/businesses/blinds-and-shades-companies/united-states)
- [Steel fabricators in the United States](https://specstream.ai/data/businesses/steel-fabricators/united-states)
